Trial intelligence / Profile preview

Surufatinib Second-Line Treatment in Unresectable or Metastatic Biliary Tract Cancer

CTR20160572Phase 2Completed

Sponsor

HUTCHMED

Start

Aug 2016

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1